UPC CFI 29/2026

Vor dem UPC: 2seventy bio, Inc. (2 Verfahren)·Janssen Group (11 Verfahren)

• 2026-09-23
  InfringementÖffentlich

  Zusammenfassung: The Brussels Local Division refused the NIH's request to be treated as co-claimant in 2seventy bio's infringement action over EP 3 689 383 (while holding it defendant in the counterclaims for revocation), and dismissed the Janssen and Legend defendants' R. 190 applications for production of evidence on entitlement and on prior notice under Art. 47 UPCA; costs were referred to the final proceedings.

  Rechtsfragen anzeigen (4)

  • Intervener cannot be reclassified as co-claimant (R. 305, R. 315 RoP); no 'aggressive' interventions
  • Presumption of entitlement under R. 8.4 RoP rebuttable on substantive law; entitlement may be raised as a defence
  • Production of evidence (R. 190 RoP) requires plausibility of the underlying claims
  • Prior notice under Art. 47(2)/(3) UPCA assessed when the action is recorded in the register; burden on the claimant